Among these medications, the third-generation targeted drug osimertinib has resulted in significant improvements in progression free survival (PFS) and overall survival (OS), both in the second-line treatment of patients with acquired T790M mutations [1, 2] and the first-line treatment of locally advanced or metastatic EGFR-mutant NSCLC [3, 4]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.